AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8931202 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical Bayes estimates from a random effects model
Number of subjects: 0
Study 8931202 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical Bayes estimates from a stochastic regression model
Number of subjects: 0
Study 1673505 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol intake (26 g alcohol daily)
Number of subjects: 87
Study 1673505 — intervention group
Group type: COMPARATOR
Intervention: Complete abstention from alcohol
Number of subjects: 87
Study 7181084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (oral and intramuscular)
Number of subjects: 0
Study 7181084 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Cimetidine
Number of subjects: 0
Study 29634593 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured toothbrushing program
Number of subjects: 0
Study 29634593 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study 29211681 — intervention group
Group type: EXPERIMENTAL
Intervention: SBWP+MM (Standard Behavioral Weight Loss Program with Mindfulness Meditation)
Number of subjects: 46
Study 29211681 — intervention group
Group type: COMPARATOR
Intervention: SBWP (Standard Behavioral Weight Loss Program)
Number of subjects: 46
Study 29211681 — intervention group
Group type: EXPERIMENTAL
Intervention: SBWP+MM
Number of subjects: 46
Study 25993386 — intervention group
Group type: EXPERIMENTAL
Intervention: Light anesthesia (BIS target of 50)
Number of subjects: 3250
Study 25993386 — intervention group
Group type: COMPARATOR
Intervention: Deep anesthesia (BIS target of 35)
Number of subjects: 3250
Study 25184862 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan plus stem-cell transplantation
Number of subjects: 273
Study 25184862 — intervention group
Group type: COMPARATOR
Intervention: MPR (melphalan-prednisone-lenalidomide)
Number of subjects: 273
Study 25184862 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance therapy
Number of subjects: 273
Study 25184862 — intervention group
Group type: COMPARATOR
Intervention: No maintenance therapy
Number of subjects: 273
Study 25184862 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan
Number of subjects: 273
Study 25184862 — intervention group
Group type: COMPARATOR
Intervention: MPR
Number of subjects: 273
Study 25184862 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance
Number of subjects: 273
Study 22529964 — intervention group
Group type: COMPARATOR
Intervention: HIV vaccine (placebo-controlled trial)
Number of subjects: 4684
Study 22529964 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 18-30 years
Number of subjects: 4684
Study 22529964 — intervention group
Group type: EXPERIMENTAL
Intervention: Having >10 partners
Number of subjects: 4684
Study 22529964 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a known HIV-positive male sex partner
Number of subjects: 4684
Study 22529964 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected anal intercourse with HIV positive/unknown male partners
Number of subjects: 4684
Study 22529964 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine use
Number of subjects: 4684
Study 22529964 — intervention group
Group type: EXPERIMENTAL
Intervention: Popper use
Number of subjects: 4684
Study 20601891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound combined with neurostimulation
Number of subjects: 93
Study 20601891 — intervention group
Group type: COMPARATOR
Intervention: Neurostimulation alone
Number of subjects: 93
Study 17907290 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophagogastric devascularization and splenectomy (EGDS)
Number of subjects: 36
Study 17907290 — intervention group
Group type: COMPARATOR
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 36
Study 16246675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin transnasal endoscopy
Number of subjects: 100
Study 16246675 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopic placement
Number of subjects: 100
Study 16246675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin transnasal endoscopy (first 10 procedures)
Number of subjects: 100
Study 16246675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin transnasal endoscopy (last 10 procedures)
Number of subjects: 100
Study 11908570 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtalar strapping insoles (n = 34)
Number of subjects: 71
Study 11908570 — intervention group
Group type: COMPARATOR
Intervention: Talonavicular strapping insoles (n = 37)
Number of subjects: 71
Study 10407505 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin therapy
Number of subjects: 363
Study 10407505 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 363
Study 7590051 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded compression leg bandages (Group 2)
Number of subjects: 24
Study 7590051 — intervention group
Group type: COMPARATOR
Intervention: No graded compression leg bandages (Group 1)
Number of subjects: 24
Study 2598983 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nifedipine (0.75 mg bolus and 1.2 mg.h‐1 infusion for 2 h)
Number of subjects: 18
Study 2598983 — intervention group
Group type: COMPARATOR
Intervention: Oral nifedipine (20 mg sustained-release)
Number of subjects: 18
Study 2598983 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone (control for intravenous study)
Number of subjects: 18
Study 2598983 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control for oral study)
Number of subjects: 18
Study 806518 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteolytic enzymes (Chymoral)
Number of subjects: 50
Study 806518 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated lactose tablets (Control)
Number of subjects: 50
Study 31010413 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once-daily (QD)
Number of subjects: 342
Study 31010413 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Duloxetine 60 mg QD (PLA_DLX)
Number of subjects: 342
Study 31010413 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD (DLX_DLX)
Number of subjects: 342
Study 28493924 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive cognitive remediation (ACR) program
Number of subjects: 135
Study 28493924 — intervention group
Group type: COMPARATOR
Intervention: Active control of ordinary computer games
Number of subjects: 135
Study 26381208 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser phototherapy (LPT) with a GaAlAs diode laser (808 nm, 100 mW, 0.04 cm², 75 J/cm², 30s per point, 3 J per point, at five points)
Number of subjects: 20
Study 26381208 — intervention group
Group type: COMPARATOR
Intervention: Control group (no irradiation)
Number of subjects: 20
Study 23674838 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressively reduced nicotine content (RNC) cigarettes
Number of subjects: 30
Study 21163595 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic genistein (30 mg daily)
Number of subjects: 84
Study 21163595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 19584379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 21042325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (weight loss phase 0-6 months)
Number of subjects: 0
Study 21042325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (weight maintenance/regain phase 7-24 months)
Number of subjects: 0
Study 21042325 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline high-molecular-weight adiponectin
Number of subjects: 0
Study 21042325 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month plasma leptin reduction
Number of subjects: 0
Study 21042325 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with greater (top tertiles) 6-month decrease in both weight and leptin
Number of subjects: 0
Study 21042325 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variations in LEP (rs4731426 and rs2071045)
Number of subjects: 0
Study 21042325 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding genetic data to the phenotypic multivariate model
Number of subjects: 0
Study 15840313 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CA(125) levels in patients with pelvic tuberculosis
Number of subjects: 492
Study 15840313 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CA(125) levels in patients with uterine adenomyosis
Number of subjects: 492
Study 15840313 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CA(125) levels in patients with ovarian endometriosis
Number of subjects: 492
Study 15840313 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CA(125) levels in patients with ovarian fibroma
Number of subjects: 492
Study 15840313 — intervention group
Group type: COMPARATOR
Intervention: Serum CA(125) levels in benign pelvic mass
Number of subjects: 492
Study 15840313 — intervention group
Group type: COMPARATOR
Intervention: Serum CA(125) levels in ovarian epithelial cancer (control group)
Number of subjects: 492
Study 12296616 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants, especially selective serotonin uptake inhibitors
Number of subjects: 0
Study 12296616 — intervention group
Group type: EXPERIMENTAL
Intervention: Early identification and treatment
Number of subjects: 0
Study 9833742 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (zidovudine + 400 mg didanosine + 400 mg nevirapine)
Number of subjects: 1313
Study 9833742 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (zidovudine + 2.25 mg zalcitabine)
Number of subjects: 1313
Study 9833742 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (zidovudine alternating monthly with 400 mg didanosine)
Number of subjects: 1313
Study 9833742 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (zidovudine + 400 mg didanosine)
Number of subjects: 1313
Study 7861603 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous administration of 20 micrograms.h‐1 of buprenorphine (Bu) with additional 20 micrograms of Bu using Baxter infusor BB+PCA
Number of subjects: 14
Study 7861603 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion of 0.4 mg of Bu and 46 ml of 0.25% bupivacaine daily (16.7 micrograms.h‐1 of Bu) using Baxter infusor 2 ml.h‐1 type
Number of subjects: 14
Study 2692200 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 70
Study 2692200 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline (PX)
Number of subjects: 70
Study 4921234 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% isoprenaline
Number of subjects: 24
Study 4921234 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% salbutamol
Number of subjects: 24
Study 4921234 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% salbutamol
Number of subjects: 24
Study 4921234 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% salbutamol
Number of subjects: 24
Study 11791962 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (30 and 35 mg/kg body weight)
Number of subjects: 40
Study 11791962 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 40
Study 30622105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0
Study 30622105 — intervention group
Group type: COMPARATOR
Intervention: Pazopanib
Number of subjects: 0
Study 30008194 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 150
Study 30008194 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 150
Study 27537841 — intervention group
Group type: EXPERIMENTAL
Intervention: elbasvir-grazoprevir for 12 weeks
Number of subjects: 301
Study 27537841 — intervention group
Group type: COMPARATOR
Intervention: placebo for 12 weeks, then open-label elbasvir-grazoprevir for 12 weeks
Number of subjects: 301
Study 27537841 — intervention group
Group type: EXPERIMENTAL
Intervention: elbasvir-grazoprevir for 12 weeks (assuming probable reinfections were responses)
Number of subjects: 301
Study 27537841 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 301
Study 23942868 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg CZP every 2 weeks (Q2W)
Number of subjects: 409
Study 23942868 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg CZP every 4 weeks (Q4W)
Number of subjects: 409
Study 23942868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 21949038 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of chemokines and cytokines (TNF‐α, IL‐1β, IL‐6, IL‐8, MCP‐1, MIP‐1α, IFN‐γ) during painful crisis or at steady state
Number of subjects: 0
Study 21949038 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of growth factors (VEGF, FGF, HGF) during painful crisis or at steady state
Number of subjects: 0
Study 21949038 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of d‐Dimer during painful crisis or at steady state
Number of subjects: 0
Study 21526671 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administered for 30 seconds (Group A)
Number of subjects: 75
Study 21526671 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administered for 60 seconds (Group B)
Number of subjects: 75
Study 21526671 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administered for 120 seconds (Group C)
Number of subjects: 75
Study 21526671 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 75
Study 18034998 — intervention group
Group type: COMPARATOR
Intervention: 4 mg renzapride
Number of subjects: 0
Study 18034998 — intervention group
Group type: COMPARATOR
Intervention: 20 mg renzapride
Number of subjects: 0
Study 18034998 — intervention group
Group type: COMPARATOR
Intervention: 0.2 microM renzapride
Number of subjects: 0
Study 18034998 — intervention group
Group type: COMPARATOR
Intervention: 2 microM renzapride
Number of subjects: 0
Study 18034998 — intervention group
Group type: COMPARATOR
Intervention: 20 microM renzapride
Number of subjects: 0
Study 18034998 — intervention group
Group type: COMPARATOR
Intervention: 1 microM cisapride
Number of subjects: 0
Study 18034998 — intervention group
Group type: COMPARATOR
Intervention: Cisapride
Number of subjects: 0
Study 14872557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin LA (bimodal release formulation)
Number of subjects: 18
Study 14872557 — intervention group
Group type: COMPARATOR
Intervention: Ritalin IR (immediate-release formulation)
Number of subjects: 18
Study 14872557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritalin LA (slow-, medium-, and fast-release formulations)
Number of subjects: 18
Study 11996211 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release metoclopramide (fasting state)
Number of subjects: 16
Study 11996211 — intervention group
Group type: COMPARATOR
Intervention: Immediate release metoclopramide
Number of subjects: 16
Study 11996211 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release metoclopramide (high-fat meal)
Number of subjects: 16
Study 9868632 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper cervical manipulation
Number of subjects: 52
Study 9868632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacroiliac manipulation
Number of subjects: 52
Study 9868632 — intervention group
Group type: COMPARATOR
Intervention: Sham/placebo
Number of subjects: 52
Study 8593718 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg orally + ketoconazole shampoo 2% daily for 4 weeks
Number of subjects: 62
Study 8593718 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg orally for 4 weeks
Number of subjects: 62
Study 8593718 — intervention group
Group type: EXPERIMENTAL
Intervention: Econazole nitrate 1% solution applied twice daily for 4 weeks
Number of subjects: 62
Study 8593718 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole nitrate 2% cream applied twice daily for 4 weeks
Number of subjects: 62
Study 2678932 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) with haloperidol (30 mg/day)
Number of subjects: 20
Study 2678932 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (30 mg/day)
Number of subjects: 20
Study 1090987 — intervention group
Group type: EXPERIMENTAL
Intervention: Five drug formulations
Number of subjects: 60
Study 1090987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30753262 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine (5 g glutamine and 10 g maltodextrin) 3 times daily from 7 days before RT to 14 days after RT
Number of subjects: 71
Study 30753262 — intervention group
Group type: COMPARATOR
Intervention: Placebo (15 g maltodextrin) 3 times daily from 7 days before RT to 14 days after RT
Number of subjects: 71
Study 30753262 — intervention group
Group type: EXPERIMENTAL
Intervention: Both glutamine and placebo groups
Number of subjects: 71
Study 28228106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (15 or 20 mg twice daily)
Number of subjects: 309
Study 28228106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 309
Study 28228106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 25907176 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg canagliflozin once-daily (q.d.)
Number of subjects: 34
Study 25907176 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg canagliflozin once-daily (q.d.)
Number of subjects: 34
Study 25907176 — intervention group
Group type: COMPARATOR
Intervention: 100 mg canagliflozin twice-daily (b.i.d.)
Number of subjects: 34
Study 25907176 — intervention group
Group type: COMPARATOR
Intervention: 300 mg canagliflozin twice-daily (b.i.d.)
Number of subjects: 34
Study 25907176 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg canagliflozin
Number of subjects: 34
Study 25907176 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg canagliflozin
Number of subjects: 34
Study 24236791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and fluorouracil with panitumumab
Number of subjects: 0
Study 24236791 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and fluorouracil without panitumumab
Number of subjects: 0
Study 24236791 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 0
Study 24236791 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 0
Study 21186164 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTS intervention
Number of subjects: 24
Study 21186164 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study 19062107 — intervention group
Group type: EXPERIMENTAL
Intervention: Active counseling and more liberal oral fluid intake
Number of subjects: 116
Study 19062107 — intervention group
Group type: COMPARATOR
Intervention: Standard fasting instructions according to hospital's procedure
Number of subjects: 116
Study 16827026 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system (FL Bond‐Shofu) applied in Group IA
Number of subjects: 30
Study 16827026 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-etch adhesive system (Prime Bond NT‐Dentsply/Caulk) applied in Group IB
Number of subjects: 30
Study 16827026 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide exposure (33% for 30 minutes daily for five consecutive days) in Group I
Number of subjects: 30
Study 16827026 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group II) received no treatment
Number of subjects: 30
Study 14688827 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C virus positivity in patients with Hodgkin's disease
Number of subjects: 111
Study 14688827 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis G virus positivity in patients with Hodgkin's disease
Number of subjects: 111
Study 14688827 — intervention group
Group type: COMPARATOR
Intervention: Comparison of hepatitis positive and negative patients
Number of subjects: 111
Study 11763945 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Maximum Strength dentifrice (5.0% potassium nitrate and 0.454% stannous fluoride in a silica base)
Number of subjects: 97
Study 11763945 — intervention group
Group type: COMPARATOR
Intervention: Fresh Mint Sensodyne dentifrice (5.0% potassium nitrate and 0.76% sodium monofluorophosphate in a dicalcium phosphate base)
Number of subjects: 97
Study 8683153 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP-mediated complement activation
Number of subjects: 9
Study 8683153 — intervention group
Group type: COMPARATOR
Intervention: mAb OKT3 infusion
Number of subjects: 9
Study 1514334 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine combined with 0.05 mg.kg‐1 meperidine
Number of subjects: 21
Study 1514334 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine combined with 0.1 mg.kg‐1 meperidine
Number of subjects: 21
Study 1514334 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine combined with 0.2 mg.kg‐1 meperidine
Number of subjects: 21
Study 1514334 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine combined with 0.3 mg.kg‐1 meperidine
Number of subjects: 21
Study 1514334 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine combined with 0.4 mg.kg‐1 meperidine
Number of subjects: 21
Study 1514334 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine combined with 0.5 mg.kg‐1 meperidine
Number of subjects: 21
Study 1514334 — intervention group
Group type: COMPARATOR
Intervention: 0.5% hyperbaric bupivacaine alone
Number of subjects: 21
Study 6441351 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 51
Study 6441351 — intervention group
Group type: COMPARATOR
Intervention: Control (no lithium carbonate)
Number of subjects: 51
Study 31287240 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 2809
Study 31287240 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression in women
Number of subjects: 2809
Study 31287240 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression in younger people
Number of subjects: 2809
Study 31287240 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression in obese people (BMI ≥30 kg/m2)
Number of subjects: 2809
Study 31287240 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive depression and obesity (BMI ≥30 kg/m2)
Number of subjects: 2809